StockGuru Spotlights for December 15, 2011
RMIOF, SMXMF, LUXD, URXE, MTIZ, PSWS, QLTS
- CTIX Up As Much As 119%
- ARIS Up As Much As 117%
- SELR UP As Much As 152%
These Spotlights have made tremendous moves. As you can see, StockGuru brings you the very stocks you want on your radar, in your portfolio and to trade.
|StockGuru Spotlight||Symbol||Spotlight Price||High||Up As Much As||Market Cap|
|October 26, 2011||CTIX||$0.34||$0.75||119%||$53.03M|
|October 21, 2011||ARIS||$0.66||$1.43||117%||$10.38M|
|October 20, 2011||SELR||$0.067||$0.169||152%||$6.58M|
|October 11, 2011||CYLU||$2.11||$3.80||80%||$68.16M|
|October 7, 2011||PYMX||$0.60||$0.71||18%||$74.62M|
PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced on December 7, 2011, that an interim analysis of results from more than 80 patients enrolled in its Phase 2 clinical trial with PMX-30063 defensin-mimetic antibiotic, indicate that all dosing arms in the study were both safe and effective in treating patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus. This is the first ever patient clinical efficacy study conducted with this new defensin-mimetic antibiotic class. PolyMedix is continuing to enroll patients and expects to complete the full trial in the first half of 2012.
Combined results from all patients enrolled in the four dosing arms showed:
There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site. We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.
StockGuru is in its Ninth Year!